Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dynasil Co. of America stock logo
DYSL
Dynasil Co. of America
$2.45
$2.53
$2.42
$2.75
$42.43M-0.09240 shsN/A
ILA
iLOOKABOUT Corp. (ILA.V)
C$0.59
+15.7%
C$0.59
C$0.11
C$0.75
C$96.75MN/A2.09 million shs1.75 million shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$4.91
+5.8%
$6.39
$3.26
$13.51
$317.43M-0.63853,115 shs495,921 shs
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dynasil Co. of America stock logo
DYSL
Dynasil Co. of America
0.00%-2.00%-2.00%-6.67%+1.24%
ILA
iLOOKABOUT Corp. (ILA.V)
0.00%0.00%0.00%0.00%0.00%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-2.32%+1.09%-24.68%-13.27%-63.44%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dynasil Co. of America stock logo
DYSL
Dynasil Co. of America
N/AN/AN/AN/AN/AN/AN/AN/A
ILA
iLOOKABOUT Corp. (ILA.V)
N/AN/AN/AN/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
4.1111 of 5 stars
3.42.00.04.13.33.30.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dynasil Co. of America stock logo
DYSL
Dynasil Co. of America
N/AN/AN/AN/A
ILA
iLOOKABOUT Corp. (ILA.V)
N/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.75
Moderate Buy$14.94204.23% Upside

Current Analyst Ratings

Latest DYSL, TERN, ILA, DXN, and CLSU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/27/2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$19.00 ➝ $18.00
3/18/2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$17.00 ➝ $15.00
3/15/2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$5.50
3/15/2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$18.00 ➝ $19.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dynasil Co. of America stock logo
DYSL
Dynasil Co. of America
N/AN/AN/AN/AN/AN/A
ILA
iLOOKABOUT Corp. (ILA.V)
C$19.51M4.96C$0.07 per share8.48C$0.11 per share5.41
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$1M317.43N/AN/A$4.13 per share1.19

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dynasil Co. of America stock logo
DYSL
Dynasil Co. of America
N/AN/A0.00N/AN/AN/AN/AN/A
ILA
iLOOKABOUT Corp. (ILA.V)
N/A-C$0.04N/AN/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$90.21M-$1.27N/AN/AN/AN/A-33.55%-31.90%5/20/2024 (Estimated)

Latest DYSL, TERN, ILA, DXN, and CLSU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/14/2024Q4 2023
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.29-$0.29N/A-$0.29N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dynasil Co. of America stock logo
DYSL
Dynasil Co. of America
N/AN/AN/AN/AN/A
ILA
iLOOKABOUT Corp. (ILA.V)
N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A

Latest DYSL, TERN, ILA, DXN, and CLSU Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/15/2024
Dynasil Co. of America stock logo
DYSL
Dynasil Co. of America
Annual$0.103.7%2/29/20243/1/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dynasil Co. of America stock logo
DYSL
Dynasil Co. of America
N/AN/AN/A
ILA
iLOOKABOUT Corp. (ILA.V)
64.23
1.87
1.76
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
22.39
22.39

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Dynasil Co. of America stock logo
DYSL
Dynasil Co. of America
N/A
ILA
iLOOKABOUT Corp. (ILA.V)
N/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%

Insider Ownership

CompanyInsider Ownership
Dynasil Co. of America stock logo
DYSL
Dynasil Co. of America
37.85%
ILA
iLOOKABOUT Corp. (ILA.V)
N/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
17.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Dynasil Co. of America stock logo
DYSL
Dynasil Co. of America
20717.32 millionN/ANot Optionable
ILA
iLOOKABOUT Corp. (ILA.V)
28163.99 millionN/ANot Optionable
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
6664.65 million53.40 millionNot Optionable

DYSL, TERN, ILA, DXN, and CLSU Headlines

SourceHeadline
Optimistic Buy Rating for Terns Pharmaceuticals Based on TERN-701 Market Potential and StrategyOptimistic Buy Rating for Terns Pharmaceuticals Based on TERN-701 Market Potential and Strategy
markets.businessinsider.com - April 26 at 4:36 PM
Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN) and BioMarin Pharmaceutical (BMRN)Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN) and BioMarin Pharmaceutical (BMRN)
markets.businessinsider.com - April 26 at 11:36 AM
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Recommendation of "Moderate Buy" by AnalystsTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Recommendation of "Moderate Buy" by Analysts
americanbankingnews.com - April 25 at 1:22 AM
Terns Pharmaceuticals Inc Ordinary SharesTerns Pharmaceuticals Inc Ordinary Shares
morningstar.com - April 18 at 6:23 PM
Intra-Cellular depression data has investors feeling goodIntra-Cellular depression data has investors feeling good
thepharmaletter.com - April 17 at 3:21 PM
Kumquat Biosciences joins forces with Takeda on I-O developmentKumquat Biosciences joins forces with Takeda on I-O development
thepharmaletter.com - April 17 at 3:21 PM
Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business OfficerTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
finanznachrichten.de - April 11 at 8:35 AM
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business OfficerTerns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
globenewswire.com - April 10 at 4:05 PM
Madrigal announces US launch of NASH/MASH drug RezdiffraMadrigal announces US launch of NASH/MASH drug Rezdiffra
msn.com - April 9 at 10:28 AM
Vivo Capital entities sell Terns Pharmaceuticals shares worth $2.8 millionVivo Capital entities sell Terns Pharmaceuticals shares worth $2.8 million
investing.com - April 5 at 10:17 AM
Vivo Opportunity, Llc Sells 138,066 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) StockVivo Opportunity, Llc Sells 138,066 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock
insidertrades.com - April 5 at 5:24 AM
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Major Shareholder Vivo Opportunity, Llc Sells 181,117 SharesTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Major Shareholder Vivo Opportunity, Llc Sells 181,117 Shares
insidertrades.com - April 4 at 6:15 AM
This small-cap stock is expected to take off - if its weight-loss pill trial succeedsThis small-cap stock is expected to take off - if its weight-loss pill trial succeeds
morningstar.com - March 30 at 7:03 PM
This small-cap stock is expected to take off — if its weight-loss pill trial succeedsThis small-cap stock is expected to take off — if its weight-loss pill trial succeeds
marketwatch.com - March 28 at 3:24 PM
UBS Group Lowers Terns Pharmaceuticals (NASDAQ:TERN) Price Target to $18.00UBS Group Lowers Terns Pharmaceuticals (NASDAQ:TERN) Price Target to $18.00
marketbeat.com - March 27 at 3:09 PM
Here’s Why Ozempic And Mounjaro Rivals Won’t Topple Weight Loss Drugmakers Novo Nordisk And Eli Lilly Anytime SoonHere’s Why Ozempic And Mounjaro Rivals Won’t Topple Weight Loss Drugmakers Novo Nordisk And Eli Lilly Anytime Soon
msn.com - March 27 at 9:31 AM
Wall Streets Favorite Biotech Stocks? 3 Names That Could Make You Filthy RichWall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
investorplace.com - March 25 at 3:00 PM
Optimistic Buy Rating for Terns Pharmaceuticals Based on Strong Clinical Pipeline and Financial StabilityOptimistic Buy Rating for Terns Pharmaceuticals Based on Strong Clinical Pipeline and Financial Stability
markets.businessinsider.com - March 21 at 6:49 AM
TERN Apr 2024 15.000 callTERN Apr 2024 15.000 call
finance.yahoo.com - March 16 at 1:45 PM
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdatesTerns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
globenewswire.com - March 14 at 4:05 PM
Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid LeukemiaTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
finanznachrichten.de - March 12 at 4:18 AM
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid LeukemiaTerns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
globenewswire.com - March 11 at 4:05 PM
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
globenewswire.com - March 7 at 4:05 PM
Terns Pharmaceuticals to Participate in Upcoming March Investor ConferencesTerns Pharmaceuticals to Participate in Upcoming March Investor Conferences
globenewswire.com - February 27 at 4:05 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Dynasil Co. of America logo

Dynasil Co. of America

OTCMKTS:DYSL
Dynasil Corporation of America develops, markets, manufactures, and sells detection, sensing, and analysis technology and optical components in the United States, Asia, Europe, and internationally. It operates through Optics, Innovation and Development, and Biomedical segments. The Optics segment supplies synthetic crystals, optical materials, components, and coatings that are used in devices, such as baggage scanners, medical imaging systems, optical instruments, lasers, analytical instruments, automotive components, semiconductor/electronic devices, spacecraft/aircraft components, and advertising displays in the medical, industrial, and homeland security/defense sectors. The Innovation and Development segment develops advanced technology in materials, sensors, and prototype instruments that detect or measure radiation, light, magnetism, or sound for use in security, medical, and industrial applications. The Biomedical segment engages in the development of tissue sealant products. The company distributes its products through direct sales and marketing staff, as well as through manufacturer's representatives and distributors. Dynasil Corporation of America was founded in 1960 and is headquartered in Newton, Massachusetts.

iLOOKABOUT Corp. (ILA.V)

CVE:ILA
iLOOKABOUT Corp., together with its subsidiaries, provides software and data licenses and technology managed services to the real estate industry in Canada and the United States. The company offers GeoViewPort, a web-based platform that enables assessment professionals to simultaneously generate customized portals to view multiple elements related to a property, including street level imagery, aerial imagery, advanced mapping tools, property valuation details, comparable property analysis, and structural characteristics. It also provides FusionOMSm, a web-based platform that enables real property valuation solutions to enterprises through US nationwide repository of public record and multiple listing service data; and Real Property Tax Analytics, a web-based platform that analyzes property assessments. In addition, the company offers data commercialization products and services through the delivery of reports and individual data requests to users through e-commerce transactions or by account, as well as customized reports through an assisted fulfillment process. Further, it provides valuation management and property tax solutions, which include assessment base management, analytics reports, tax policy planning and support, and appeals management. It primarily serves property lending and property tax sectors. iLOOKABOUT Corp. was founded in 2000 and is based in London, Canada.
Terns Pharmaceuticals logo

Terns Pharmaceuticals

NASDAQ:TERN
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.